{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T05:20:43Z","timestamp":1695705643180},"reference-count":29,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,1,10]],"date-time":"2018-01-10T00:00:00Z","timestamp":1515542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"National Health Security Office (NHSO), Bangkok, Thailand"},{"name":"The Aligning Care and Prevention of HIV\/AIDS with Government Decentralization to Achieve Coverage and Impact: ACHIEVED Project (The Global fund Project, Thailand)"},{"name":"Government Budget\/Medical Research Network","award":["GRB_APS_06_58_30_03"],"award-info":[{"award-number":["GRB_APS_06_58_30_03"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tropical Med Int Health"],"published-print":{"date-parts":[[2018,3]]},"abstract":"Abstract<\/jats:title>Objective<\/jats:title>In Thailand, 7.2% of HIV<\/jats:styled-content> patients are co\u2010infected with hepatitis C virus (HCV<\/jats:styled-content>), and these patients are treated with peg\u2010interferon + ribavirin (PR<\/jats:styled-content>) for their HCV<\/jats:styled-content> infection. This study evaluates efficacy and safety of PR<\/jats:styled-content> treatment and pharmacokinetics of ribavirin in this population.<\/jats:p><\/jats:sec>Methods<\/jats:title>HIV<\/jats:styled-content>\/HCV<\/jats:styled-content> co\u2010infected Thai patients were treated with PR<\/jats:styled-content> for 24 or 48 weeks. Sustained virological response 24 weeks after the end of treatment (SVR<\/jats:styled-content>24) was used to describe efficacy. (laboratory) safety parameters and ribavirin plasma concentrations were evaluated during study visits. Ribavirin concentrations were compared with t<\/jats:italic>\u2010tests for patients with and without anaemia (haemoglobin <10 g\/dl) and SVR<\/jats:styled-content>24.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 101 HIV<\/jats:styled-content>\/HCV<\/jats:styled-content> co\u2010infected patients were included; 88% were male (n<\/jats:italic> = 88), and 46% were infected with genotype 3. The median (IQR<\/jats:styled-content>) start dose was 14.28 mg\/kg\/day. SVR<\/jats:styled-content>24 rate was 56%. All patients reported at least one (serious) adverse event, of which 28% of patients developed anaemia. Seven patients discontinued treatment due to toxicity issues. Geometric mean (IQR<\/jats:styled-content>) ribavirin concentration was 1.81 (1.42\u20132.32) mg\/l at week 8 of treatment. At week 8, patients with and without anaemia and SVR<\/jats:styled-content> had ribavirin concentrations of 2.29 and 1.63 mg\/l and 1.91 and 1.74 mg\/l, respectively.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>PR<\/jats:styled-content> treatment has comparable response rates and toxicity profile in Thai HIV<\/jats:styled-content>\/HCV<\/jats:styled-content> co\u2010infected patients as in Western HIV<\/jats:styled-content>\/HCV<\/jats:styled-content> patients. However, ribavirin plasma concentrations were comparable with previously published studies in HIV<\/jats:styled-content>\/HCV<\/jats:styled-content> co\u2010infected patients, but both, just as SVR<\/jats:styled-content> rate, were lower than in mono\u2010infected patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tmi.13027","type":"journal-article","created":{"date-parts":[[2017,12,16]],"date-time":"2017-12-16T22:48:22Z","timestamp":1513464502000},"page":"295-305","source":"Crossref","is-referenced-by-count":5,"title":["Peg\u2010interferon and ribavirin treatment in HIV<\/scp>\/HCV<\/scp> co\u2010infected patients in Thailand: efficacy, safety and pharmacokinetics"],"prefix":"10.1111","volume":"23","author":[{"given":"E. J.","family":"Smolders","sequence":"first","affiliation":[{"name":"Department of Pharmacy & Radboud Institute for Health Sciences Radboud University Medical Center Nijmegen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Thammajaruk","sequence":"additional","affiliation":[{"name":"HIV\u2010Netherlands Australia Thailand Research Collaboration Thai Red Cross AIDS Research Centre Bangkok Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. T. M. M.","family":"de Kanter","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University Medical Center Utrecht Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Colbers","sequence":"additional","affiliation":[{"name":"Department of Pharmacy & Radboud Institute for Health Sciences Radboud University Medical Center Nijmegen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Chaiyahong","sequence":"additional","affiliation":[{"name":"HIV\u2010Netherlands Australia Thailand Research Collaboration Thai Red Cross AIDS Research Centre Bangkok Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Cuprasitrut","sequence":"additional","affiliation":[{"name":"HIV\u2010Netherlands Australia Thailand Research Collaboration Thai Red Cross AIDS Research Centre Bangkok Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Chittmittraprap","sequence":"additional","affiliation":[{"name":"HIV\u2010Netherlands Australia Thailand Research Collaboration Thai Red Cross AIDS Research Centre Bangkok Thailand"},{"name":"Department of Biochemistry Faculty of Medicine Chulalongkorn University Bangkok Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Apornpong","sequence":"additional","affiliation":[{"name":"HIV\u2010Netherlands Australia Thailand Research Collaboration Thai Red Cross AIDS Research Centre Bangkok Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Khemnark","sequence":"additional","affiliation":[{"name":"Department of Medicine Bamrasnaradura Institute Nonthaburi Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Tangkijvanich","sequence":"additional","affiliation":[{"name":"Department of Biochemistry Faculty of Medicine Chulalongkorn University Bangkok Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. M.","family":"Burger","sequence":"additional","affiliation":[{"name":"Department of Pharmacy & Radboud Institute for Health Sciences Radboud University Medical Center Nijmegen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Avihingsanon","sequence":"additional","affiliation":[{"name":"HIV\u2010Netherlands Australia Thailand Research Collaboration Thai Red Cross AIDS Research Centre Bangkok Thailand"},{"name":"Department of Medicine Faculty of Medicine Chulalongkorn University Bangkok Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,1,10]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00485-5"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200405210-00010"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0149362"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.01.073"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12168"},{"key":"e_1_2_7_7_1","first-page":"153","article-title":"EASL recommendations on treatment of hepatitis C 2016","volume":"66","author":"Pawlotsky JM","year":"2016","journal-title":"J Hepatol"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.10.034"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(98)80341-3"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.06.034"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000226"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-012-0631-y"},{"key":"e_1_2_7_13_1","doi-asserted-by":"crossref","unstructured":"HauserG AwadT BrokJet al.Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C. The Cochrane Library. 2014(2).","DOI":"10.1002\/14651858.CD005441.pub3"},{"key":"e_1_2_7_14_1","unstructured":"Thailand. Practice guideline for the management of chronic hepatitis B and C 2012(Available from:http:\/\/www.thasl.org\/files\/24.HBV_and_HCV_Guideline_2012(update).pdf)."},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510240201"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ultrasmedbio.2003.07.001"},{"key":"e_1_2_7_17_1","unstructured":"Division of Aids.Division of Aids table for grading the severity of adult and pediatric adverse events; Version 1.0. December 2004."},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2006.03.019"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.01.005"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2014.17"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.23.2839"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032653"},{"key":"e_1_2_7_23_1","unstructured":"FDA.Copegus: Prescribing information 2011(Available from:http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm)."},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12128"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133879"},{"key":"e_1_2_7_26_1","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1471-2334-14-150","article-title":"Lower ribavirin biodisponibility in patients with HIV\u2010HCV coinfection in comparison with HCV monoinfected patients","volume":"14","author":"Hatu G","year":"2014","journal-title":"BMC Infect Dis"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000170034.90438.68"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks045"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1159\/000081741"},{"key":"e_1_2_7_30_1","unstructured":"FDA.Epclusa: Prescribing information 2016(Available from:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/208341s000lbl.pdf)."}],"container-title":["Tropical Medicine & International Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftmi.13027","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tmi.13027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T20:40:28Z","timestamp":1695674428000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tmi.13027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,10]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1111\/tmi.13027"],"URL":"https:\/\/doi.org\/10.1111\/tmi.13027","archive":["Portico"],"relation":{},"ISSN":["1360-2276","1365-3156"],"issn-type":[{"value":"1360-2276","type":"print"},{"value":"1365-3156","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,10]]}}}